You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Emerging therapies for breast cancer
|
|---|---|
| Published in |
Journal of Hematology & Oncology, April 2017
|
| DOI | 10.1186/s13045-017-0466-3 |
| Pubmed ID | |
| Authors |
Xichun Hu, Wei Huang, Minhao Fan |
| Abstract |
HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 116 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 22 | 19% |
| Researcher | 13 | 11% |
| Student > Ph. D. Student | 10 | 9% |
| Student > Master | 10 | 9% |
| Student > Doctoral Student | 9 | 8% |
| Other | 16 | 14% |
| Unknown | 37 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 22% |
| Biochemistry, Genetics and Molecular Biology | 15 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 8% |
| Agricultural and Biological Sciences | 5 | 4% |
| Immunology and Microbiology | 5 | 4% |
| Other | 12 | 10% |
| Unknown | 45 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2017.
All research outputs
#20,418,183
of 22,968,808 outputs
Outputs from Journal of Hematology & Oncology
#1,038
of 1,196 outputs
Outputs of similar age
#270,141
of 310,521 outputs
Outputs of similar age from Journal of Hematology & Oncology
#35
of 39 outputs
Altmetric has tracked 22,968,808 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,196 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,521 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.